Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real‐world experience

Documenti analoghi

• Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli‐ SWITCH study
  di: Martin Haluzík, et al.
  Pubblicazione: (2025)
• Safety and clinical effectiveness of iGlarLixi in people with type 2 diabetes mellitus in Mexico
  di: Juan Rosas‐Guzman, et al.
  Pubblicazione: (2025)
• Effect of iGlarLixi on continuous glucose monitoring—measured time in range in insulin‐naive adults with suboptimally controlled type 2 diabetes
  di: Juan P. Frías, et al.
  Pubblicazione: (2025)
• Real‐life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use
  di: Jochen Seufert, et al.
  Pubblicazione: (2024)
• Efficacy and safety of iGlarLixi versus IDegAsp by baseline β‐cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli‐D study
  di: Weijun Gu, et al.
  Pubblicazione: (2025)